Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,791 total articles
3 E Network Technology Group Limited announced a $1 million private placement led by its CEO, Dr. Tingjun Yang, to strengthen its AI strategy. The capital will support ongoing R&D and commercialization of AI computing chips and applications. Recent milestones include advancements in edge AI SoCs, cloud AI storage controllers, a green AI data center…
AGM Group Holdings Inc. announced that their full-stack AI storage solutions are gaining market traction, driven by rising demand for high-performance data storage used in large AI model R&D and cloud services. The company has started mass production of all-flash servers and has secured procurement agreements with enterprise and regional computing …
Emergent BioSolutions has completed a repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, reducing the outstanding debt balance to approximately $364.7 million. The company executed this repurchase at an average price of 90.6% of face value, deploying about $68 million of cash, demonstrating disciplin…
Hillman Solutions Corp., a leading hardware product provider, has completed its acquisition of Kanebridge, LLC, a master distributor of industrial fasteners, for approximately $315 million. This strategic move significantly expands Hillman's industrial addressable market to around $3 billion and establishes its first U.S. master distribution platfo…
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York. The company is advancing its clinical-stage programs for proprietary serotonergic agonists aimed at treating depression and anxiety, including a Phase 3 candidate with FDA Breakthrough Therapy Designation…
The FDA has granted Fast Track designation to Liquidia Corporation's inhaled powder drug YUTREPIA (treprostinil) for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a condition with significant unmet medical need and no approved therapies in the United States. This designation will help expedite the development an…
Crescent Biopharma, a clinical-stage biotech company focusing on innovative cancer therapies, announced its management will present at the 2026 Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference in September. The presentations will highlight the company's pipeline developments including a PD-1 x VEGF bispecific anti…
Structure Therapeutics, a clinical-stage biopharmaceutical company focused on oral small molecule therapeutics for metabolic diseases, will participate in three leading healthcare investment conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and Bernstein’s Healthcare Forum. Management will hold fir…
TG Therapeutics announced that CEO Michael S. Weiss will participate in a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026. The company is a commercial-stage biotech focused on treatments for B-cell diseases, with its FDA-approved drug BRIUMVI for relapsing multiple sclerosis.
Rekor Systems, Inc. has terminated its two remaining long-term real estate leases in the US and Israel, resulting in elimination of ongoing rent obligations and generating over $2 million in annual cost savings. The company used $2.8 million in cash to reduce $10 million in lease liabilities, improving operating leverage and aligning cost structure…
Electra Battery Materials Corporation is progressing with the construction of Canada’s only cobalt sulfate refinery in Ontario as part of its strategic plan to strengthen North America's critical minerals supply chain. The company is actively engaging with investors, industry participants, and government bodies through multiple September conference…
Eikon Therapeutics announced the appointment of Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer. Dr. Chang brings over 20 years of experience in academic medicine and biopharmaceutical drug discovery, having held key roles at Bristol Myers Squibb, Gilead Sciences, and MyoKardia. His extensive expertise in translational …
Trevi Therapeutics announced that senior executives will participate in several major healthcare and IPF-related conferences in September 2026, presenting updates on their investigational therapy Haduvio™ (oral nalbuphine ER) intended to treat chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough. The company highlighted the …
Dyne Therapeutics announced preclinical data supporting the development of four novel investigational therapies targeting Duchenne Muscular Dystrophy (DMD) mutations amenable to exon skipping of 44, 45, 53, and 55. These candidates, based on the same FORCE™ platform as their lead drug under FDA review, demonstrated promising in vitro and in vivo re…
Saia, Inc. releases its less-than-truckload (LTL) shipment and tonnage data for July and August 2026, showing increases in shipments per workday, tonnage per workday, and weight per shipment compared to the same months in 2025. These gains indicate solid operational performance in the third quarter so far, though the company cautions actual results…
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026. The company is preparing for a Phase 3 pivotal trial for its lead drug ATH434, which has shown promising results in Phase 2 trials for Multiple Sy…
Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for its unified technology platform that addresses healthcare fragmentation by integrating consumer experiences, clinician workflows, care programs, and partner solutions. The award highlights Amwell’s innovation and business impact in creating a connected infrastr…
GXO Logistics, Inc. has expanded its technology organization by appointing Balaji Rangaswamy as Chief Information Officer. The restructuring focuses on enhancing the company's enterprise systems to support scalable growth and resilience while accelerating innovation, particularly in areas like AI and robotics. This move underlines GXO's commitment …
Avalo Therapeutics announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and Morgan Stanley Annual Global Healthcare Conference. The company focuses on developing IL-1β pathway therapeutics for immune-mediated inflammatory diseases and is advancing its lead candidate, abdakibart, int…
Victoria's Secret & Co. reported a strong second quarter in 2026 with net sales increasing 10% to $1.611 billion, operating income rising to $257 million, and adjusted operating income surpassing guidance at $124 million. The company has raised its full-year 2026 net sales and adjusted operating income guidance, citing growth across all business se…
Breckenridge Distillery, a craft spirits brand under Tilray Brands, announced an expanded distribution partnership with Southern Glazer’s Wine & Spirits in New York and California. This expansion aims to increase market penetration and consumer access to its broad portfolio including bourbon, vodka, and ready-to-drink offerings in two of the larges…
Climb Bio announced positive Phase 1 trial data for its anti-APRIL monoclonal antibody, CLYM116, showing a ~29-day half-life and sustained APRIL suppression with favorable safety. The data supports an every-12-week dosing regimen for treating IgA nephropathy. The Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027, and a Phase…
LeonaBio, a clinical-stage biopharmaceutical company listed on NASDAQ, announced its participation in the Cantor Global Healthcare Conference 2026. Management will engage in a fireside chat to discuss their novel therapeutic developments targeting diseases with high unmet medical needs, including metastatic breast cancer and ALS. The event will fea…
C4 Therapeutics announced it will present new biomarker data demonstrating the immunomodulatory effects of its investigational drug cemsidomide, combined with dexamethasone, from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd International Myeloma Society Annual Meeting. The data highlights the drug's impact on T and NK cells, s…
Eledon Pharmaceuticals announced multiple milestones for its lead drug candidate tegoprubart, including IND submission to FDA for an islet cell transplantation trial, enrollment of first patients in investigator-initiated studies, compassionate use dosing in transplant patients with renal dysfunction and high sensitization, and reaffirmed plans to …
